Filip Vrbacky
Overview
Explore the profile of Filip Vrbacky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al.
J Clin Invest
. 2024 Oct;
134(23).
PMID: 39436708
Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL...
2.
Blazek M, Vrbacky F, Fatorova I, Mirska K, Zak P
Int J Lab Hematol
. 2023 Nov;
46(2):243-249.
PMID: 37921205
Background: Coronavirus disease 2019 (COVID-19) is a life-threatening disease with a heterogeneous course. Even some young patients are at increased risk of severe course or death, as they can face...
3.
Vrbacky F, Fatorova I, Blazek M, Smahel P, Zak P
J Infect Public Health
. 2022 Apr;
15(5):533-538.
PMID: 35461075
Background: Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is still a very dangerous and life-threatening disease with an extremely heterogeneous course. Older patients and those with comorbidities are...
4.
Simkovic M, Vodarek P, Motyckova M, Ecsiova D, Rozsivalova P, Mocikova H, et al.
Eur J Clin Invest
. 2020 Oct;
51(4):e13421.
PMID: 33022756
High doses of corticosteroids in combination with rituximab remain an alternative in the treatment in relapsed or refractory chronic lymphocytic leukaemia (CLL) in the current era of targeted therapies. This...
5.
Panovska A, Nemcova L, Nekvindova L, Spacek M, Simkovic M, Papajik T, et al.
Hematol Oncol
. 2020 May;
38(4):509-516.
PMID: 32400885
Until recently, a combination of anti-CD20 antibody plus less intensive chemotherapy was a standard of care in elderly population with previously untreated chronic lymphocytic leukemia (CLL). The aim of this...
6.
Kukla R, Bolehovska R, Radocha J, Pliskova L, Zak P, Vrbacky F, et al.
New Microbiol
. 2020 Apr;
43(2):70-77.
PMID: 32310299
The aim of this study was to test the detection performance of the cpsA, lytA and ply genes through qPCR in the identification of Streptococcus pneumoniae in respiratory tract samples....
7.
Baranova I, Kovarikova H, Laco J, Sedlakova I, Vrbacky F, Kovarik D, et al.
Clin Chem Lab Med
. 2020 Mar;
58(8):1332-1340.
PMID: 32145055
Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early...
8.
Fajfr M, Pliskova L, Bolehovska R, Uhlirova Z, Vrbacky F
J Glob Antimicrob Resist
. 2019 May;
19:269-273.
PMID: 31100505
Introduction And Aim: Infections caused by herpes simplex viruses (HSV) are frequent in the human population. Because of the widespread use of long-term treatment or prophylaxis by anti-herpetic antivirals in...
9.
Belohlavkova P, Steinerova K, Karas M, Skoumalova I, Rohon P, Indrak K, et al.
Leuk Res
. 2019 May;
81:67-74.
PMID: 31051328
We retrospectively evaluated the role of age and dosage in 372 CML patients (170 women, 202 men) treated with first-line imatinib (IMA) from the records of the CAMELIA registry. The...
10.
Belohlavkova P, Vrbacky F, Voglova J, Racil Z, Zackova D, Hrochova K, et al.
Arch Med Sci
. 2018 Nov;
14(6):1416-1423.
PMID: 30393497
Introduction: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. Material And Methods:...